Fused pyrimidine-based drug discovery /

Fused Pyrimidine-Based Drug Discovery covers all categories of fused-pyrimidines along with pharmacological and in silico studies. It covers the chemistry and biological activities, as well as the design of novel fused-pyrimidine scaffolds. N-Heterocyclic scaffolds are found in most known drug candi...

Full description

Bibliographic Details
Corporate Author:	ScienceDirect (Online service)
Other Authors:	Kumar, Raj (Associate professor) (Editor)
Format:	eBook
Language:	English
Published:	Amsterdam, Netherlands : Elsevier, [2023]
Series:	Heterocyclic drug discovery.
Subjects:	Drug development. Pyrimidines. Pyrimidines Médicaments > Développement. Drug development Electronic books.
Online Access:	Connect to the full text of this electronic book

Table of Contents:

4.5.1 G-protein coupled receptor (GPCR)119 agonists
4.5.2 Anti-cancer agents
4.5.3 Anti-HCV activity
4.5.4 Epidermal growth factor receptor (EGFR) inhibitors
4.6 Triazolo[1,5-a]pyrimidines, pyrazolo[1,5-a]pyrimidines, and pyrimido[1,2-a]benzimidazoles
4.6.1 Anti-cancer activity
4.6.2 Antitubercular activity
4.7 Pyrazolothienopyrimidine
4.8 Thiazolo[3,2-a]pyrimidines
4.8.1 Antimicrobial activity
4.8.2 Anticancer activity
4.8.3 Anti-inflammatory agents
4.8.4 Antibacterial and antitubercular agents
4.9 Thiazolo[4,5-d]pyrimidines
4.9.1 Cyclooxygenase inhibitors
4.10 Pyrido[4',3':4,5]thieno[2,3-d]pyrimidines
4.11 Recent patents
Acknowledgments
References
5
FDA approved five-membered ring fused pyrimidine-based derivatives and their biological properties
5.1 Sildenafil
5.2 Valganciclovir
5.3 Duvelisib
5.4 Vidarabine
5.5 Abacavir
5.6 Entecavir
5.7 Ganciclovir
5.8 Acyclovir
5.9 Theophylline
5.10 Pemetrexed
5.11 Zanubrutinib
5.12 Cangrelor
5.13 Ticagrelor
5.14 Fludarabine
5.15 Valaciclovir
5.16 Nelarabine
5.17 Cladribine
5.18 Istradefylline
5.19 Penciclovir
5.20 Tofacitinib
5.21 Ribociclib
5.22 Tenofovir alafenamide
5.23 Ibrutinib
5.24 Udenafil
5.25 Allopurinol
5.26 Ruxolitinib
5.27 Baricitinib
5.28 Zaleplon
5.29 Azathioprine
5.30 Thioguanine
5.31 Anagliptin
5.32 Regadenoson
5.33 Adefovir dipivoxil
5.34 Clofarabine
5.35 Idelalisib
5.36 Didanosine
5.37 Famciclovir
5.38 Dyphylline
5.39 Pentoxifylline
5.40 Caffeine
5.41 Enprofylline
References
6
Benzene fused pyrimidine-based derivatives and their biological properties
6.1 Preface
6.2 Zorifertinib (AZD3759)
6.3 CZh226
6.4 2-amino-4-methylquinazoline derivatives.
6.5 (S)-3-((2-amino-8-fluoroquinazolin-4-yl)amino)hexan-1-ol
6.6 7-methoxy-4-(2-methylquinazolin-4-yl)-3,4-dihydroquinoxalin-2(1H)-one
6.7 BMS-919373
6.8 1-(4-((3-Chlorophenyl)amino)quinazolin-6-yl)-3-(3,5- difluorophenyl)thiourea
6.9 N-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)- phenyl)-2-(pyridin-4-yl)quinazolin-4-amine
6.10 GSK2983559
References
7
Six-membered ring (with N, O or S) fused pyrimidine-based derivatives and biological properties
7.1 Introduction
7.2 Classification
7.2.1 Nitrogen-containing six-membered rings fused with pyrimidine
7.2.1.1 Pyrido-pyrimidines
7.2.1.1.1 Pyrido[3,4-d]pyrimidines
7.2.1.1.2 Pyrido[2,3-d]pyrimidines
7.2.1.1.3 Pyrido[3,2-d]pyrimidines
7.2.1.1.4 Pyrido[4,3-d] pyrimidines
7.2.1.2 Pyrimidopyrimidines
7.2.1.2.1 Pyrimidio[1,6-a] and [1,6-c]pyrimidines
7.2.1.2.2 Pyrimido[4,5-d]pyrimidines
7.2.1.2.3 Pyrimido[5,4-d]Pyrimidines
7.2.1.2.4 Pyrimido[1,2-a]pyrimidines
7.2.1.3 Pteridine
7.2.2 Oxygen-containing six-membered ring fused with pyrimidine
7.2.2.1 Chromeno[2,3-d]pyrimidines
7.2.2.2 Pyrano[3,2-d]pyrimidines
7.2.2.3 Pyrano[2,3-d]pyrimidines
7.2.3 Sulphur containing six-membered rings fused with a pyrimidine
7.2.3.1 Thiopyrano[3,2-d]pyrimidines
References
8
FDA approved six-membered ring fused pyrimidine-based derivatives
8.1 Methotrexate
8.2 Risperidone
8.3 Pemirolast
8.4 Pralatrexate
8.5 Trametinib
8.6 Triamterene
8.7 Palbociclib
8.8 Dipyridamole
8.9 Prazosin
8.10 Alfuzosin
8.11 Trimetrexate
8.12 Anagrelide
8.13 Quinethazone
8.14 Copanlisib
8.15 Terazosin
8.16 Doxazosin
8.17 Gefitinib
8.18 Erlotinib
8.19 Afatinib
8.20 Dacomitinib
8.21 Vandetanib
8.22 Lapatinib
8.23 Idelalisib
8.24 Raltitrexed
8.25 Asasantin
References.
9
Seven-membered ring fused pyrimidine-based derivatives and their biological properties
9.1 Introduction
9.2 Pyrimidine fused with a seven-membered ring containing nitrogen
9.3 Pyrimidine fused with a seven-membered ring containing oxygen
9.4 Pyrimidine fused with a seven-membered ring containing nitrogen and oxygen
9.5 Pyrimidine fused with a seven-membered ring containing sulphur
9.6 Pyrimidine fused with a seven-membered ring containing nitrogen and sulfur
References
10
Eight-membered fused pyrimidine derivatives and their biological properties
10.1 Introduction
10.2 Exploring the reported literature on eight-membered heterocycles fused with a pyrimidine ring
10.3 Tricyclic pyrimidine-fused eight-membered diazocines
10.3.1 Eight-membered rings (azocine)
10.4 Conclusion
References
11
Molecular modeling studies of fused pyrimidine derivatives at various receptors
11.1 Abacavir
11.1.1 Mechanism of action
11.1.2 Binding mode analysis
11.2 Acyclovir
11.2.1 Mechanism of action
11.2.2 Binding mode analysis
11.3 Adefovir dipivoxil
11.3.1 Mechanism of action
11.3.2 Binding mode analysis
11.4 Allopurinol
11.4.1 Mechanism of action
11.4.2 Binding mode analysis
11.5 Anagliptin
11.5.1 Mechanism of action
11.5.2 Binding mode analysis
11.6 Azathioprine
11.6.1 Mechanism of action
11.6.2 Binding mode analysis
11.7 Baricitinib
11.7.1 Mechanism of action
11.7.2 Binding mode analysis
11.8 Caffeine
11.8.1 Mechanism of action
11.8.2 Binding mode analysis
11.9 Cangrelor
11.9.1 Mechanism of action
11.9.2 Binding mode analysis
11.10 Cladribine
11.10.1 Mechanism of action
11.10.2 Binding mode analysis
11.11 Clofarabine
11.11.1 Mechanism of action
11.11.2 Binding mode analysis
11.12 Didanosine.
11.12.1 Mechanism of action
11.12.2 Binding mode analysis
11.13 Dipyridamole
11.13.1 Mechanism of action
11.13.2 Binding mode analysis
11.14 Duvelisib
11.14.1 Mechanism of action
11.14.2 Binding mode analysis
11.15 Dyphylline
11.15.1 Mechanism of action
11.15.2 Binding mode analysis
11.16 Enprofylline
11.16.1 Mechanism of action
11.16.2 Binding mode analysis
11.17 Entecavir
11.17.1 Mechanism of action
11.17.2 Binding mode analysis
11.18 Fludarabine
11.18.1 Mechanism of action
11.18.2 Binding mode analysis
11.19 Ganciclovir
11.19.1 Mechanism of action
11.19.2 Binding mode analysis
11.20 Ibrutinib
11.20.1 Mechanism of action
11.20.2 Binding mode analysis
11.21 Idelalisib
11.21.1 Mechanism of action
11.21.2 Binding mode analysis
11.22 Istradefylline
11.22.1 Mechanism of action
11.22.2 Binding mode analysis
11.23 Methotrexate
11.23.1 Mechanism of action
11.23.2 Binding mode analysis
11.24 Nelarabine
11.24.1 Mechanism of action
11.24.2 Binding mode analysis
11.25 Palbociclib
11.25.1 Mechanism of action
11.25.2 Binding mode analysis
11.26 Pemetrexed
11.26.1 Mechanism of action
11.26.2 Binding mode analysis
11.27 PEMIROLAST
11.27.1 Mechanism of action
11.27.2 Binding mode analysis
11.28 Penciclovir
11.28.1 Mechanism of action
11.28.2 Binding mode analysis
11.29 Pentoxifylline
11.29.1 Mechanism of action
11.29.2 Binding mode analysis
11.30 Pralatrexate
11.30.1 Mechanism of action
11.30.2 Binding mode analysis
11.31 Regadenoson
11.31.1 Mechanism of action
11.31.2 Binding mode analysis
11.32 Ribociclib
11.32.1 Mechanism of action
11.32.2 Binding mode analysis
11.33 Risperidone
11.33.1 Mechanism of action
11.33.2 Binding mode analysis
11.34 Ruxolitinib.